Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Piper Sandler biotech analysts hold an analyst/industry conference call » 14:55
07/15/21
07/15
14:55
07/15/21
14:55
LOGC

LogicBio Therapeutics

$3.76 /

-0.15 (-3.84%)

, SRPT

Sarepta

$67.86 /

+1.03 (+1.54%)

, NTLA

Intellia Therapeutics

$135.19 /

-5.81 (-4.12%)

, VERV

Verve Therapeutics

$47.67 /

-1.86 (-3.76%)

Biotech Analyst Rahimi,…

Biotech Analyst Rahimi, along with Mark A. Kay, MD, PhD, discuss Cardiovascular Gene Therapy on an Analyst/Industry conference call to be held on July 15 at 3 pm. Webcast Link

ShowHide Related Items >><<
VERV Verve Therapeutics
$47.67 /

-1.86 (-3.76%)

SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

06/07/21
Fly Intel: Top five analyst initiations
06/07/21 H.C. Wainwright
LogicBio Therapeutics initiated with a Buy at H.C. Wainwright
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
03/04/21 JMP Securities
LogicBio Therapeutics initiated with an Outperform at JMP Securities
SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

07/01/21 Berenberg
Sarepta assumed with a Hold at Berenberg
06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
VERV Verve Therapeutics
$47.67 /

-1.86 (-3.76%)

07/12/21 JPMorgan
Verve Therapeutics initiated with a Neutral at JPMorgan
07/12/21 Jefferies
Verve Therapeutics initiated with a Buy at Jefferies
07/12/21 Guggenheim
Verve Therapeutics initiated with a Buy at Guggenheim
07/12/21 William Blair
Verve Therapeutics initiated with an Outperform at William Blair
SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

  • 30
    Jun
  • 17
    Jun
  • 02
    Dec
  • 01
    Oct
VERV Verve Therapeutics
$47.67 /

-1.86 (-3.76%)

SRPT Sarepta
$67.86 /

+1.03 (+1.54%)

NTLA Intellia Therapeutics
$135.19 /

-5.81 (-4.12%)

LOGC LogicBio Therapeutics
$3.76 /

-0.15 (-3.84%)

Conference/Events
Piper Sandler biotech analysts hold an analyst/industry conference call » 10:36
07/15/21
07/15
10:36
07/15/21
10:36
LOGC

LogicBio Therapeutics

$3.91 /

+ (+0.00%)

, SRPT

Sarepta

$67.30 /

+0.47 (+0.70%)

, NTLA

Intellia Therapeutics

$140.18 /

-0.82 (-0.58%)

, VERV

Verve Therapeutics

$49.02 /

-0.51 (-1.03%)

Biotech Analyst Rahimi,…

Biotech Analyst Rahimi, along with Mark A. Kay, MD, PhD, discuss Cardiovascular Gene Therapy on an Analyst/Industry conference call to be held on July 15 at 3 pm. Webcast Link

ShowHide Related Items >><<
VERV Verve Therapeutics
$49.02 /

-0.51 (-1.03%)

SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

06/07/21
Fly Intel: Top five analyst initiations
06/07/21 H.C. Wainwright
LogicBio Therapeutics initiated with a Buy at H.C. Wainwright
04/27/21 Chardan
LogicBio collaborations may signal recognition of platforms, says Chardan
03/04/21 JMP Securities
LogicBio Therapeutics initiated with an Outperform at JMP Securities
SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

07/01/21 Berenberg
Sarepta assumed with a Hold at Berenberg
06/14/21 BTIG
Sarepta initiated with a Buy at BTIG
05/18/21 William Blair
William Blair says continued lack of '9001 safety signals positive for Sarepta
05/03/21 William Blair
Sarepta data confirm potential of PPMO platform, says William Blair
NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

06/30/21 Piper Sandler
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler
06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
VERV Verve Therapeutics
$49.02 /

-0.51 (-1.03%)

07/12/21 JPMorgan
Verve Therapeutics initiated with a Neutral at JPMorgan
07/12/21 Jefferies
Verve Therapeutics initiated with a Buy at Jefferies
07/12/21 Guggenheim
Verve Therapeutics initiated with a Buy at Guggenheim
07/12/21 William Blair
Verve Therapeutics initiated with an Outperform at William Blair
SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

  • 30
    Jun
  • 17
    Jun
  • 02
    Dec
  • 01
    Oct
VERV Verve Therapeutics
$49.02 /

-0.51 (-1.03%)

SRPT Sarepta
$67.30 /

+0.47 (+0.70%)

NTLA Intellia Therapeutics
$140.18 /

-0.82 (-0.58%)

LOGC LogicBio Therapeutics
$3.91 /

+ (+0.00%)

Recommendations
Bicycle Therapeutics price target raised to $40 from $36 at Canaccord » 08:34
07/15/21
07/15
08:34
07/15/21
08:34
BCYC

Bicycle Therapeutics

$34.00 /

+1.35 (+4.13%)

, IONS

Ionis Pharmaceuticals

$35.26 /

-1.14 (-3.13%)

Canaccord analyst Arlinda…

Canaccord analyst Arlinda Lee raised the firm's price target on Bicycle Therapeutics to $40 from $36 and keeps a Buy rating on the shares. The analyst raised the price target following the announcement of the purchase of a worldwide license agreement for its TfR1 receptor which included an upfront payment of $45M.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$35.26 /

-1.14 (-3.13%)

BCYC Bicycle Therapeutics
$34.00 /

+1.35 (+4.13%)

BCYC Bicycle Therapeutics
$34.00 /

+1.35 (+4.13%)

07/14/21 Benchmark
Bicycle deal 'makes little sense' for Ionis, says Benchmark
07/13/21 William Blair
Bicycle collaboration a positive for Ionis, says William Blair
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
07/13/21 Canaccord
Bicycle Therapeutics price target raised to $36 from $30 at Canaccord
IONS Ionis Pharmaceuticals
$35.26 /

-1.14 (-3.13%)

07/02/21 RBC Capital
RBC trims Arrowhead target to $83, but says ENaC pause 'not thesis changing'
IONS Ionis Pharmaceuticals
$35.26 /

-1.14 (-3.13%)

BCYC Bicycle Therapeutics
$34.00 /

+1.35 (+4.13%)

IONS Ionis Pharmaceuticals
$35.26 /

-1.14 (-3.13%)

BCYC Bicycle Therapeutics
$34.00 /

+1.35 (+4.13%)

IONS Ionis Pharmaceuticals
$35.26 /

-1.14 (-3.13%)

Recommendations
Bicycle deal 'makes little sense' for Ionis, says Benchmark » 07:34
07/14/21
07/14
07:34
07/14/21
07:34
IONS

Ionis Pharmaceuticals

$36.37 /

-0.9 (-2.41%)

, BCYC

Bicycle Therapeutics

$32.66 /

+1.02 (+3.22%)

After Ionis…

After Ionis Pharmaceuticals (IONS) announced a deal to pay $45M upfront for in-licensing from Bicycle Therapeutics (BCYC) a peptide technology that appears to be intended to increase the delivery capabilities of Ionis' LICA drugs, Benchmark analyst Aydin Huseynov said "strategically and financially this makes little sense" given Ionis has said that its strategy was to invest in its own pipeline and technologies. Even if this collaboration expands the LICA platform, it still adds more value to Bicycle than to Ionis, according to Huseynov, who keeps a Hold rating on Ionis shares.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$36.37 /

-0.9 (-2.41%)

BCYC Bicycle Therapeutics
$32.66 /

+1.02 (+3.22%)

IONS Ionis Pharmaceuticals
$36.37 /

-0.9 (-2.41%)

07/13/21 William Blair
Bicycle collaboration a positive for Ionis, says William Blair
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
07/02/21 RBC Capital
RBC trims Arrowhead target to $83, but says ENaC pause 'not thesis changing'
06/11/21 BMO Capital
Ionis Pharmaceuticals coverage transferred at BMO Capital
BCYC Bicycle Therapeutics
$32.66 /

+1.02 (+3.22%)

07/13/21 Canaccord
Bicycle Therapeutics price target raised to $36 from $30 at Canaccord
05/11/21 Oppenheimer
Bicycle Therapeutics price target raised to $44 from $38 at Oppenheimer
IONS Ionis Pharmaceuticals
$36.37 /

-0.9 (-2.41%)

BCYC Bicycle Therapeutics
$32.66 /

+1.02 (+3.22%)

IONS Ionis Pharmaceuticals
$36.37 /

-0.9 (-2.41%)

BCYC Bicycle Therapeutics
$32.66 /

+1.02 (+3.22%)

IONS Ionis Pharmaceuticals
$36.37 /

-0.9 (-2.41%)

Recommendations
Bicycle collaboration a positive for Ionis, says William Blair » 12:30
07/13/21
07/13
12:30
07/13/21
12:30
IONS

Ionis Pharmaceuticals

$36.68 /

-0.59 (-1.58%)

, BCYC

Bicycle Therapeutics

$32.20 /

+0.56 (+1.77%)

After Ionis (IONS)…

After Ionis (IONS) announced an updated partnership with Bicycle Therapeutics (BCYC) that will grant Ionis a worldwide license and collaboration agreement for the company's high-affinity transferrin receptor Bicycle peptide to be used to expand Ionis's extra-hepatic LICA capabilities to both muscle and central nervous system tissue, William Blair analyst Myles Minter said he views the collaboration as a positive and indicative of the company acknowledging that extra-hepatic LICA technologies could be a significant differentiator from peers. The analyst, who adds that it remains to be seen is if TfR1 can "revolutionize drug delivery to muscle and CNS tissue," maintains a Market Perform rating on Ionis shares.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$36.68 /

-0.59 (-1.58%)

BCYC Bicycle Therapeutics
$32.20 /

+0.56 (+1.77%)

IONS Ionis Pharmaceuticals
$36.68 /

-0.59 (-1.58%)

07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
07/02/21 RBC Capital
RBC trims Arrowhead target to $83, but says ENaC pause 'not thesis changing'
06/11/21 BMO Capital
Ionis Pharmaceuticals coverage transferred at BMO Capital
06/10/21 Benchmark
Biogen's Aduhelm approval has 'nothing to do' with Ionis, says Benchmark
BCYC Bicycle Therapeutics
$32.20 /

+0.56 (+1.77%)

07/13/21 Canaccord
Bicycle Therapeutics price target raised to $36 from $30 at Canaccord
05/11/21 Oppenheimer
Bicycle Therapeutics price target raised to $44 from $38 at Oppenheimer
05/07/21 Piper Sandler
Bicycle Therapeutics price target raised to $39 from $35 at Piper Sandler
IONS Ionis Pharmaceuticals
$36.68 /

-0.59 (-1.58%)

BCYC Bicycle Therapeutics
$32.20 /

+0.56 (+1.77%)

IONS Ionis Pharmaceuticals
$36.68 /

-0.59 (-1.58%)

BCYC Bicycle Therapeutics
$32.20 /

+0.56 (+1.77%)

IONS Ionis Pharmaceuticals
$36.68 /

-0.59 (-1.58%)

Recommendations
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler » 10:18
07/13/21
07/13
10:18
07/13/21
10:18
BCYC

Bicycle Therapeutics

$33.00 /

+1.36 (+4.30%)

, IONS

Ionis Pharmaceuticals

$36.57 /

-0.7 (-1.88%)

, RHHBY

Roche

$48.54 /

+0.395 (+0.82%)

, AZN

AstraZeneca

$60.29 /

-0.22 (-0.36%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Bicycle Therapeutics (BCYC) to $46 from $39 and keeps an Overweight rating on the shares after the company announced that it has entered into an exclusive licensing agreement with Ionis Pharmaceuticals (IONS) for delivery of antisense oligonucleotides to muscle. Ionis joins Bicycle's other "strong partners" including Roche (RHHBY) and AstraZeneca (AZN), said Tenthoff, whose target increase is due to adding value for Bicycle's partnerships.

ShowHide Related Items >><<
RHHBY Roche
$48.54 /

+0.395 (+0.82%)

IONS Ionis Pharmaceuticals
$36.57 /

-0.7 (-1.88%)

BCYC Bicycle Therapeutics
$33.00 /

+1.36 (+4.30%)

AZN AstraZeneca
$60.29 /

-0.22 (-0.36%)

BCYC Bicycle Therapeutics
$33.00 /

+1.36 (+4.30%)

07/13/21 Canaccord
Bicycle Therapeutics price target raised to $36 from $30 at Canaccord
05/11/21 Oppenheimer
Bicycle Therapeutics price target raised to $44 from $38 at Oppenheimer
05/07/21 Piper Sandler
Bicycle Therapeutics price target raised to $39 from $35 at Piper Sandler
04/20/21 JMP Securities
Bicycle Therapeutics initiated with an Outperform at JMP Securities
IONS Ionis Pharmaceuticals
$36.57 /

-0.7 (-1.88%)

07/02/21 RBC Capital
RBC trims Arrowhead target to $83, but says ENaC pause 'not thesis changing'
06/11/21 BMO Capital
Ionis Pharmaceuticals coverage transferred at BMO Capital
06/10/21 Benchmark
Biogen's Aduhelm approval has 'nothing to do' with Ionis, says Benchmark
05/07/21 UBS
Ionis Pharmaceuticals upgraded to Neutral from Sell at UBS
RHHBY Roche
$48.54 /

+0.395 (+0.82%)

07/08/21 Deutsche Bank
Roche upgraded to Buy from Hold at Deutsche Bank
06/30/21 Jefferies
Pieris Pharmaceuticals price target raised to $8 from $6 at Jefferies
06/14/21 Berenberg
Roche price target raised to CHF 340 from CHF 320 at Berenberg
06/10/21 Morgan Stanley
Roche price target raised to CHF 370 from CHF 345 at Morgan Stanley
AZN AstraZeneca
$60.29 /

-0.22 (-0.36%)

06/17/21 UBS
AstraZeneca price target raised to 9,200 GBp from 8,000 GBp at UBS
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
05/05/21 Oppenheimer
Alexion upgraded to Outperform from Perform at Oppenheimer
04/30/21 Wedbush
Alexion's Q1 report 'uneventful' after FTC grants deal clearance, says Wedbush
RHHBY Roche
$48.54 /

+0.395 (+0.82%)

IONS Ionis Pharmaceuticals
$36.57 /

-0.7 (-1.88%)

BCYC Bicycle Therapeutics
$33.00 /

+1.36 (+4.30%)

AZN AstraZeneca
$60.29 /

-0.22 (-0.36%)

RHHBY Roche
$48.54 /

+0.395 (+0.82%)

AZN AstraZeneca
$60.29 /

-0.22 (-0.36%)

RHHBY Roche
$48.54 /

+0.395 (+0.82%)

IONS Ionis Pharmaceuticals
$36.57 /

-0.7 (-1.88%)

BCYC Bicycle Therapeutics
$33.00 /

+1.36 (+4.30%)

AZN AstraZeneca
$60.29 /

-0.22 (-0.36%)

IONS Ionis Pharmaceuticals
$36.57 /

-0.7 (-1.88%)

AZN AstraZeneca
$60.29 /

-0.22 (-0.36%)

Hot Stocks
Ionis Pharmaceuticals enters exclusive licensing pact with Bicycle Therapeutics » 07:10
07/13/21
07/13
07:10
07/13/21
07:10
IONS

Ionis Pharmaceuticals

$37.28 /

-1.595 (-4.10%)

, BCYC

Bicycle Therapeutics

$31.64 /

+0.69 (+2.23%)

Ionis Pharmaceuticals…

Ionis Pharmaceuticals (IONS) announced that it has entered into an exclusive licensing agreement with Bicycle Therapeutics (BCYC) to increase the delivery capabilities of Ionis' advanced LIgand Conjugated Antisense, or LICA, medicines. The agreement provides Ionis exclusive access to Bicycle's proprietary macrocyclic peptides, referred to as Bicycles, to design LICAs that target transferrin receptor 1 for use with oligonucleotides. This LICA strategy has demonstrated both the improved delivery of antisense medicines to muscle tissue, including cardiac muscle, as well as the potential to cross the blood brain barrier. Under terms of the agreement, Ionis obtained an exclusive license to Bicycle's technology covering the entire class of transferrin receptor 1 Bicycles for use in targeted delivery of oligonucleotide drugs. Ionis made a $45M upfront payment to Bicycle which included a license fee, an option fee, and an $11M equity investment in Bicycle. Bicycle will be eligible to earn development and regulatory milestone payments on a program-by-program basis and royalties on product sales.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$37.28 /

-1.595 (-4.10%)

BCYC Bicycle Therapeutics
$31.64 /

+0.69 (+2.23%)

IONS Ionis Pharmaceuticals
$37.28 /

-1.595 (-4.10%)

07/02/21 RBC Capital
RBC trims Arrowhead target to $83, but says ENaC pause 'not thesis changing'
06/11/21 BMO Capital
Ionis Pharmaceuticals coverage transferred at BMO Capital
06/10/21 Benchmark
Biogen's Aduhelm approval has 'nothing to do' with Ionis, says Benchmark
05/07/21 UBS
Ionis Pharmaceuticals upgraded to Neutral from Sell at UBS
BCYC Bicycle Therapeutics
$31.64 /

+0.69 (+2.23%)

07/13/21 Canaccord
Bicycle Therapeutics price target raised to $36 from $30 at Canaccord
05/11/21 Oppenheimer
Bicycle Therapeutics price target raised to $44 from $38 at Oppenheimer
05/07/21 Piper Sandler
Bicycle Therapeutics price target raised to $39 from $35 at Piper Sandler
04/20/21 JMP Securities
Bicycle Therapeutics initiated with an Outperform at JMP Securities
IONS Ionis Pharmaceuticals
$37.28 /

-1.595 (-4.10%)

BCYC Bicycle Therapeutics
$31.64 /

+0.69 (+2.23%)

IONS Ionis Pharmaceuticals
$37.28 /

-1.595 (-4.10%)

BCYC Bicycle Therapeutics
$31.64 /

+0.69 (+2.23%)

IONS Ionis Pharmaceuticals
$37.28 /

-1.595 (-4.10%)

Recommendations
RBC trims Arrowhead target to $83, but says ENaC pause 'not thesis changing' » 12:20
07/02/21
07/02
12:20
07/02/21
12:20
ARWR

Arrowhead

$60.83 /

-24.12 (-28.39%)

, IONS

Ionis Pharmaceuticals

$39.99 /

-0.07 (-0.17%)

RBC Capital analyst Luca…

RBC Capital analyst Luca Issi lowered the firm's price target on Arrowhead (ARWR) to $83 from $90 and keeps an Outperform rating on the shares after the company announced it is voluntarily pausing the ongoing Phase I/II trial exploring EnAC for cystic fibrosis due to local lung inflammation seen during chronic dosing in rats. While the pause is "unfortunate," it is not totally unexpected given that Ionis Pharmaceuticals (IONS) also discontinued its ENaC for a pre-clinical toxicity and it is "not thesis changing," Issi tells investors. While he lowered his target as he removed EnAC and lowered his view of platform odds of success, Issi would be a buyer into the weakness as his long-term thesis is unchanged.

ShowHide Related Items >><<
IONS Ionis Pharmaceuticals
$39.99 /

-0.07 (-0.17%)

ARWR Arrowhead
$60.83 /

-24.12 (-28.39%)

ARWR Arrowhead
$60.83 /

-24.12 (-28.39%)

07/02/21 B. Riley
Arrowhead selloff presents buying opportunity, says B. Riley
07/02/21 Piper Sandler
Arrowhead price target lowered to $89 from $109 at Piper Sandler
06/25/21 Piper Sandler
Arrowhead to present ARO-AAT data at EASL, says Piper Sandler
06/21/21 Piper Sandler
Arrowhead price target raised to $109 from $99 at Piper Sandler
IONS Ionis Pharmaceuticals
$39.99 /

-0.07 (-0.17%)

06/11/21 BMO Capital
Ionis Pharmaceuticals coverage transferred at BMO Capital
06/10/21 Benchmark
Biogen's Aduhelm approval has 'nothing to do' with Ionis, says Benchmark
05/07/21 UBS
Ionis Pharmaceuticals upgraded to Neutral from Sell at UBS
03/29/21 Piper Sandler
Ionis' Phase 2 data for PKK-LRx 'impressive' at face value, says Piper Sandler
IONS Ionis Pharmaceuticals
$39.99 /

-0.07 (-0.17%)

ARWR Arrowhead
$60.83 /

-24.12 (-28.39%)

ARWR Arrowhead
$60.83 /

-24.12 (-28.39%)

IONS Ionis Pharmaceuticals
$39.99 /

-0.07 (-0.17%)

ARWR Arrowhead
$60.83 /

-24.12 (-28.39%)

IONS Ionis Pharmaceuticals
$39.99 /

-0.07 (-0.17%)

Recommendations
Poseida Therapeutics being overlooked after Intellia data, says Piper Sandler » 13:19
06/30/21
06/30
13:19
06/30/21
13:19
PSTX

Poseida Therapeutics

$9.51 /

-0.39 (-3.94%)

, NTLA

Intellia Therapeutics

$184.60 /

+32.96 (+21.74%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating and $17 price target on Poseida Therapeutics (PSTX), as the analyst feels the stock, which has proprietary piggyBac transposon and Cas-CLOVER gene editing technologies, is being overlooked in the aftermath of Intellia's (NTLA) in-vivo Phase 1 data on CRISPR/Cas9 therapy NTLA-2001 for the treatment of hATTR amyloidosis. Poseida has demonstrated human proof-of-concept with autologous CAR-T P-BCMA-101 in multiple myeloma and P-PSMA-101 in prostate cancer that Tenthoff believes differentiates from other CAR-T products and de-risks future allogeneic products, the analyst tells investors in a research note.

ShowHide Related Items >><<
PSTX Poseida Therapeutics
$9.51 /

-0.39 (-3.94%)

NTLA Intellia Therapeutics
$184.60 /

+32.96 (+21.74%)

PSTX Poseida Therapeutics
$9.51 /

-0.39 (-3.94%)

06/23/21 Piper Sandler
Piper says 'time to take a fresh look' at Poseida after CEO meeting
05/18/21 Piper Sandler
Poseida Therapeutics transferred with Overweight rat Piper Sandler
05/17/21 BTIG
Poseida Therapeutics initiated with a Buy at BTIG
05/17/21 BTIG
Poseida Therapeutics initiated with a Buy at BTIG
NTLA Intellia Therapeutics
$184.60 /

+32.96 (+21.74%)

06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
06/29/21 Raymond James
Intellia Therapeutics price target raised to $168 from $106 at Raymond James
PSTX Poseida Therapeutics
$9.51 /

-0.39 (-3.94%)

NTLA Intellia Therapeutics
$184.60 /

+32.96 (+21.74%)

  • 30
    Jun
  • 02
    Dec
  • 10
    Jul
PSTX Poseida Therapeutics
$9.51 /

-0.39 (-3.94%)

NTLA Intellia Therapeutics
$184.60 /

+32.96 (+21.74%)

Syndicate
Intellia Therapeutics 4.14M share Secondary priced at $145.00 » 06:11
06/30/21
06/30
06:11
06/30/21
06:11
NTLA

Intellia Therapeutics

$151.66 /

+18.46 (+13.86%)

The deal size was…

The deal size was increased to $600M from $400M and priced below last closing price of $151.61. Goldman Sachs, Jefferies, SVB Leerink and Barclays are acting as joint book running managers for the offering.

ShowHide Related Items >><<
NTLA Intellia Therapeutics
$151.66 /

+18.46 (+13.86%)

NTLA Intellia Therapeutics
$151.66 /

+18.46 (+13.86%)

06/29/21 Cowen
Alnylam weakness a buying opportunity, says Cowen
06/29/21 Wedbush
Beam Therapeutics price target raised to $149 from $114 at Wedbush
06/29/21 Oppenheimer
Intellia Therapeutics price target raised to $125 from $73 at Oppenheimer
06/29/21 Raymond James
Intellia Therapeutics price target raised to $168 from $106 at Raymond James
NTLA Intellia Therapeutics
$151.66 /

+18.46 (+13.86%)

  • 30
    Jun
  • 02
    Dec
NTLA Intellia Therapeutics
$151.66 /

+18.46 (+13.86%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.